12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CRLX101: Phase II ongoing

Cerulean began the second stage in 19 additional patients of an open-label, U.S. Phase II trial evaluating 15 mg/m 2 IV CRLX101 every 2 weeks in up to 29 ovarian cancer patients who have progressed following first-line platinum-based therapy. The company said the first patient to achieve 6...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >